Exact Sciences Co. (NASDAQ:EXAS) Stock Holdings Raised by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG raised its stake in Exact Sciences Co. (NASDAQ:EXAS) by 1.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 129,024 shares of the medical research company’s stock after purchasing an additional 1,547 shares during the period. Bank Pictet & Cie Europe AG owned 0.07% of Exact Sciences worth $7,250,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Huntington National Bank increased its position in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of Exact Sciences in the 3rd quarter worth about $34,000. Capital Performance Advisors LLP bought a new stake in shares of Exact Sciences in the 3rd quarter worth about $35,000. Vestor Capital LLC bought a new stake in shares of Exact Sciences in the 3rd quarter worth about $46,000. Finally, V Square Quantitative Management LLC bought a new stake in shares of Exact Sciences during the 3rd quarter valued at about $47,000. Institutional investors own 88.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EXAS. Robert W. Baird lowered their price objective on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. TD Cowen boosted their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Barclays began coverage on shares of Exact Sciences in a research report on Thursday, January 23rd. They set an “overweight” rating and a $70.00 price objective for the company. Canaccord Genuity Group lowered their price objective on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Trading Down 2.5 %

Shares of NASDAQ:EXAS opened at $49.31 on Friday. The company has a 50 day moving average of $56.15 and a 200-day moving average of $60.09. The firm has a market cap of $9.13 billion, a P/E ratio of -42.14 and a beta of 1.24. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.